tradingkey.logo

Bluejay Diagnostics Inc

BJDX

1.490USD

-0.010-0.67%
Horário de mercado ETCotações atrasadas em 15 min
825.48KValor de mercado
PerdaP/L TTM

Bluejay Diagnostics Inc

1.490

-0.010-0.67%
Mais detalhes de Bluejay Diagnostics Inc Empresa
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
Informações da empresa
Código da empresaBJDX
Nome da EmpresaBluejay Diagnostics Inc
Data de listagemNov 10, 2021
CEOMr. Neil (Indranil) Dey
Número de funcionários7
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 10
Endereço360 Massachusetts Avenue, Suite 203
CidadeACTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01720
Telefone19786310152
Sitehttps://bluejaydx.com/
Código da empresaBJDX
Data de listagemNov 10, 2021
CEOMr. Neil (Indranil) Dey
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Detalhamento da receita
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Armistice Capital LLC
0.47%
L1 Capital Global Opportunities Master Fund Ltd.
0.18%
Tower Research Capital LLC
0.12%
UBS Financial Services, Inc.
0.05%
Lana Management & Business Research International LLC
0.03%
Other
99.15%
Investidores
Investidores
Proporção
Armistice Capital LLC
0.47%
L1 Capital Global Opportunities Master Fund Ltd.
0.18%
Tower Research Capital LLC
0.12%
UBS Financial Services, Inc.
0.05%
Lana Management & Business Research International LLC
0.03%
Other
99.15%
Tipos de investidores
Investidores
Proporção
Hedge Fund
0.58%
Corporation
0.21%
Investment Advisor
0.05%
Individual Investor
0.04%
Other
99.11%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
29
13.35K
0.89%
-11.19K
2025Q1
33
13.32K
1.15%
-11.19K
2024Q4
33
13.25K
2.40%
-10.14K
2024Q3
34
31.07K
8.08%
+26.51K
2024Q2
34
7.19K
9.21%
+4.96K
2024Q1
32
2.22K
59.41%
+553.00
2023Q4
32
1.63K
54.54%
+399.00
2023Q3
33
1.19K
46.18%
+12.00
2023Q2
32
1.16K
61.50%
-18.00
2023Q1
29
1.15K
45.43%
-4.00
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Armistice Capital LLC
6.95K
0.47%
+6.95K
--
Sep 30, 2024
L1 Capital Global Opportunities Master Fund Ltd.
2.68K
0.18%
+2.68K
--
Jun 27, 2024
Tower Research Capital LLC
1.74K
0.12%
+1.19K
+213.90%
Mar 31, 2025
UBS Financial Services, Inc.
812.00
0.05%
-1.13K
-58.25%
Mar 31, 2025
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
Wurth (Douglas Clark)
414.00
0.03%
--
--
May 02, 2025
Chase (Donald R)
98.00
0.01%
--
--
May 02, 2025
Dey (Indranil)
90.00
0.01%
--
--
May 02, 2025
SBI Securities Co., Ltd.
20.00
0%
+20.00
--
Mar 31, 2025
Cook (Jason John)
13.00
0%
--
--
May 02, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Data
Tipo
Proporção
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jul 21, 2023
Merger
20<1
Jul 21, 2023
Merger
20<1
Ver Mais
KeyAI